MRI-Guided Biopsy

DEVICE2 trials

Sponsors

University Health Network, Toronto, University of Miami

Conditions

Prostate CancerRecurrent Prostate Cancer

Unknown Phase

MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy

CompletedNCT00775866

University Health Network, TorontoRecurrent Prostate Cancer

Start: 2006-10-31End: 2017-09-15Updated: 2017-11-29

MRI Based Active Selection for Treatment Trial

CompletedNCT02242773

University of MiamiProstate Cancer

Start: 2014-11-12End: 2024-05-22Updated: 2025-07-11

Related Papers

Abstract 691: Visualizing differential prostate cancer lesion growth in longitudinal MRIs of patients on active surveillance: Quantitative mapping by Habitat Risk Score and digital pathology.

Cancer Research2026-04-03

Gene expression signatures in biopsy cores as predictors of coexisting higher-grade disease in Gleason group 1 prostate cancer: Results from the Miami MAST prospective clinical trial.

Journal of Clinical Oncology2025-02-10

Validation of PAM50 for predicting progression in active surveillance: Results from the Miami MAST prospective clinical trial.

Journal of Clinical Oncology2025-02-10

Assessing molecular heterogeneity of prostate cancer biopsy sampling: Insights from the MAST trial.

Journal of Clinical Oncology2025-02-10

Grade and volume progression and its association with the Decipher genomic classifier using patients enrolled in a prospective active surveillance protocol.

Journal of Clinical Oncology2025-02-10

HRS Improves Active Surveillance for Prostate Cancer by Timely Identification of Progression.

2024-12-17

(128) CORRELATION BETWEEN BIOPSY FREQUENCY AND REDUCED SEXUAL FUNCTION IN PROSTATE CANCER PATIENTS UNDER ACTIVE SURVEILLANCE: A PROSPECTIVE COHORT STUDY

The Journal of Sexual Medicine2024-08-12

MP41-12 ASSESSING MOLECULAR HETEROGENEITY OF PROSTATE CANCER BIOPSY SAMPLING: INSIGHTS FROM THE MAST TRIAL

The Journal of Urology2024-04-15

Plasma Exosomal RNA Biomarkers of High-Risk Prostate Cancer.

2021-11-01

Abstract LB065: Prostate cancer molecular immunophenotypes in biopsies with high vs average radiation sensitivity as predicted by post-operative radiation therapy outcomes (PORTOS) scores

Cancer Research2021-07-01